Vonafexor induces improvements in liver fat content, kidney function in NASH

Vonafexor induces improvements in liver fat content, kidney function in NASH

Vonafexor induced a strong reduction in liver fat content and improvements in biochemical and imaging markers of liver inflammation and kidney function, according to a presenter at The Liver Meeting Digital Experience.“The primary endpoint of hepatic fat decrease was met at week 12 in patients with presumed fibrosis treated with bone effects or 100 mg and 200 mg,” Stephen A. Harrison, MD, medical director at Pinnacle Clinical Research in San Antonio, Texas, said during the presentation.“There were consistent improvements of the noninvasive fibro inflammatory markers.Read More

Share on facebook
Share on twitter
Share on linkedin